1. The JAK/STAT signaling pathway: from bench to clinic;Hu;Signal Transduct Target Ther,2021
2. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis;Fleischmann;N Engl J Med,2012
3. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis;Ytterberg;N Engl J Med,2022
4. Janus kinase (JAK) inhibitors: drug safety communication - FDA Requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death, FDA. 2021. https://www.fda.gov/safety/medical-product-safety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk. Accessed May 25, 2022.